# Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma

> **NCT00390416** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 48 (actual)

## Conditions studied

- Stomach Neoplasms
- Esophageal Neoplasms

## Interventions

- **DRUG:** Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin

## Key facts

- **NCT ID:** NCT00390416
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2016-03-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00390416

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00390416, "Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00390416. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*